KBC Group’s Mineralys Therapeutics MLYS Stock Holding History

KBC Group’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33K	Hold	1,233	–	–	﹤0.01%	1813
2026 Q1	$33K	Buy	+1,233	New	+$36.2K	﹤0.01%	1778

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

KBC Group's MLYS Position: Q2 2026 in Review

KBC Group held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 1,233 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #1813.

KBC Group first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

KBC Group held 1,233 shares of Mineralys Therapeutics worth $33K as of Q2 2026.
KBC Group left its Mineralys Therapeutics share count unchanged in Q2 2026.
Mineralys Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1813 holding.
KBC Group first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.